Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Olympus faces another superbug lawsuit
A Washington woman last week leveled the latest lawsuit against Olympus (TYO:7733) over a deadly “superbug” infection she allegedly acquired from 1 of the company’s endoscopes during a gallstone operation.
A flurry of the so-called superbug infections across the country in recent months, including several deaths, have prompted several lawsuits against Olympus over its TJF-Q180V duodenoscope. Read more
2. Osprey Medical fishes up $11m private placement
Osprey Medical said it raised about $11 million (A$14 million) in a private placement for its Avert device, which is designed to prevent contrast-induced nephropathy in patients with chronic kidney disease.
Minneapolis- and Melbourne-based Osprey said the oversubscribed, 10.8-million-share round included backing from “international and domestic institutions and accredited and sophisticated investors,” including its 2 largest shareholders, Brandon Managed Funds and Talu Venture (formally CM Capital). Read more
1. AtriCure launches CryoIce treatment for pain
Ohio’s AtriCure is promoting 1 of its cryoablation devices for a new indication, temporary pain relief for some cardiac surgery patients.
AtriCure said its CryoIce ablation probe is designd to temporarily manage pain through cryoanalgesia, or ablating the affected nerves. The technique can pause the transmission of pain impulses to the brain for days or even weeks, the company said. Read more
